NCT06365541

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Exploring the Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients: an Open, Prospective, and Self-controlled Study

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: The People's Hospital of Gaozhou · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure. Many studies have shown that dapagliflozin has cardioprotective effect, but most studies focus on non-dialysis patients with eGFR more than 20ml/min/1.73m2. However, the data on patients with eGFR less than 20ml/min/1.73m2 or dialysis patients, especially peritoneal dialysis patients, is less. Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance.

Conditions

• The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Interventions

Type	Name	Description
DRUG	Dapagliflozin	oral Dapagliflozin tablets 10mg/day for 6 months

Timeline

• Start date: 2024-03-01
• Primary completion: 2024-08-31
• Completion: 2024-08-31
• First posted: 2024-04-15
• Last updated: 2024-04-15

Locations

1 site across 1 country: China